• Patrys’ deoxymabs data on vasculitis disease presented
  • Next Science’s BLASTX data published

 

Patrys’ deoxymabs data presented

Patrys (ASX:PAB) jumped 12% this morning after announcing that new data from preclinical studies using PAT-DX1 and PAT-DX3 (both called deoxymabs) in animal models were presented by Dr Kim O’Sullivan from Monash University during the plenary session at the 21st International Vasculitis Workshop in Barcelona.

The presentation demonstrated positive preclinical data for deoxymabs in the autoimmune disease, anti-neutrophil cytoplasmic antibody (ANCA) vasculitis.

Previously, Patrys has shown that its deoxymabs suppress the formation of neutrophil extracellular traps (NETs).

NETs are structures comprised of DNA strands and certain proteins produced by neutrophils. Recent studies have indicated that NETs may play an important role in the establishment and maintenance of cancer cells, the spreading of cancer (metastasis) and in regulating inflammation.

As the formation of NETs is one of the underlying processes in the development of the autoimmune disease ANCA vasculitis, Dr O’Sullivan extended these findings by examining the impact of Patrys’ deoxymabs in an animal model of the disease.

The key results from these studies include:

  • PAT-DX1 and PAT-DX3 are both able to inhibit the formation of NETs in an animal model of ANCA vasculitis;
  • Both deoxymabs reduced the level of inflammation and kidney injury in the animal model of ANCA vasculitis;
  • However, neither PAT-DX1 nor PAT-DX3 had any detrimental effect on neutrophils indicating that their administration did not result in any suppression of the immune system.

“We are particularly excited by the discovery that both PAT-DX1 and PAT-DX3 are able to reduce symptoms of inflammation without negatively impacting the immune system as this is one of the major side-effects of existing therapies for vasculitis,” said Dr Sullivan.

 

Next Science’s BLASTX data published

Meanwhile, Next Science (ASX:NXS) announced the publication of a study which found BLASTX to be efficacious in the treatment of pressure ulcers, when used in conjunction with negative pressure wound therapy (NPWT).

The study has been published in Diagnostics, an international peer-reviewed journal, by Dr Thomas E. Serena.

The primary objective of the study was to determine whether adding an anti-microbial agent would decrease both planktonic and biofilm bacteria in a wound, and increase the efficacy of NPWT.

Fluorescence imaging was used to track bacterial burden and inform therapy. The 20-patient study focused on the treatment of pressure ulcers which affects millions of people in the US each year.

The study found that 45% of the pressure ulcers reduced in size over the four-week study with “a resolution of bacterial fluorescence in the NPWT dressing and wound bed seen in an average of three weeks”.

Dr Serena concluded that the combination of BLASTX and NPWT “reduced bacterial levels and improved wound healing in recalcitrant pressure ulcers”.

BLASTX is an antimicrobial wound gel powered by Next Science’s patented, non-toxic XBIO Technology.

It deconstructs the bacterial biofilm extracellular polymeric substance (EPS), destroys bacteria enveloped within the gel, and defends against recolonisation while maintaining a moist wound environment.

 

Share prices today:

 

 

Read MoreBiotech

Featured Companies

You might be interested in